-+ 0.00%
-+ 0.00%
-+ 0.00%
Hutchmed Drugs Qualify for China's Reimbursement List With Expanded Coverage
Share
Listen to the news
01:24 AM EST, 11/16/2026 (MT Newswires) -- Hutchmed (China)'s (HCM.L) Elunate, Orpathys, and Sulanda retained their spots in China's updated national reimbursement drug list under their existing multi-year agreements, with expanded coverage for new indications. Effective Jan. 1, 2027, Elunate will also be cleared for reimbursement for certain patients with locally advanced or metastatic renal cell carcinoma, according to a Monday release. Meanwhile, Orpathys will be newly included in the list for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR-TKI therapy, in combination with osimertinib. The biopharmaceutical company jointly developed Orpathys with AstraZeneca (AZN.L, AZN.ST) and Elunate with Eli Lilly (LLY.F, LLY.SW).
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending